| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Reactive oxygen species (ROS) and free radicals. Antioxidant peptide A does not target a specific protein receptor but functions as a direct chemical antioxidant. Its cysteine (thiol) and methionine (sulfur) residues are believed to be critical for radical scavenging activity.
|
|---|---|
| ln Vitro |
In cancer cells, Antioxidant peptide A exhibits strong radical scavenging activities. The side chains of the peptide, particularly those containing aromatic or sulfur-containing amino acids, enhance free radical scavenging activity. Detailed mechanistic or quantitative data (e.g., IC50 values) are not publicly available.
|
| ln Vivo |
No detailed in vivo animal data are available. Antioxidant peptide A has potential applications in food preservation as a natural preservative due to its ability to inhibit oxidation in food products, as well as potential health benefits in combating oxidative stress in medical research.
|
| Enzyme Assay |
DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assay: The peptide is incubated with DPPH radical solution in methanol or ethanol for 30 minutes. The decrease in absorbance at 517 nm is measured spectrophotometrically. ABTS cation radical decolorization assay: ABTS radical is generated by reacting ABTS with potassium persulfate. Peptide is added, and absorbance at 734 nm is measured after 6 minutes.
|
| Cell Assay |
Cancer cell lines (e.g., HeLa, MCF-7, A549) are treated with Antioxidant peptide A TFA (typically 10-200 uM) for 24-48 hours. Intracellular ROS levels are measured using fluorescent probes such as DCFH-DA (2',7'-dichlorofluorescin diacetate). Cell viability is assessed by MTT or CellTiter-Glo. Reduced glutathione (GSH) levels may also be measured.
|
| Animal Protocol |
No standardized animal protocols exist. For preclinical studies of oxidative stress or cancer, the peptide could be administered via intraperitoneal or intravenous injection (dose not established). Endpoints would include measurement of oxidative stress markers (e.g., malondialdehyde, protein carbonyls, or 8-OHdG) in plasma or tissues, tumor growth in xenograft models, or survival.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data available. As a short hexapeptide (MW ~884.99 g/mol), Antioxidant peptide A is likely to have rapid plasma degradation by peptidases and a very short half-life (minutes). It is not expected to have oral bioavailability and would require injection for in vivo applications.
|
| Toxicity/Toxicokinetics |
No toxicity data reported. As a peptide with sequence PHCKRM (similar to motifs found in naturally occurring antioxidant proteins), it is expected to have low inherent toxicity. High doses might cause off-target effects via thiol oxidation. Standard safety precautions for handling peptides apply.
|
| References |
[1]. Kalmodia S, et al. Bio-conjugation of antioxidant peptide on surface-modified gold nanoparticles: a novel approach to enhance the radical scavenging property in cancer cell. Cancer Nanotechnol. 2016;7:1.
|
| Additional Infomation |
Antioxidant peptide A TFA is a research-grade peptide, not FDA-approved. It has potential applications in both food science (as a natural preservative) and medicine (for combating oxidative stress-related diseases). The trifluoroacetate salt form enhances solubility and stability. Strictly for research use.
|
| Molecular Formula |
C33H55F3N12O9S2
|
|---|---|
| Molecular Weight |
884.99
|
| Related CAS # |
Antioxidant peptide A;159147-88-3
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :≥ 100 mg/mL (~113.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1300 mL | 5.6498 mL | 11.2996 mL | |
| 5 mM | 0.2260 mL | 1.1300 mL | 2.2599 mL | |
| 10 mM | 0.1130 mL | 0.5650 mL | 1.1300 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
